17641-39-3

Usage

Uses

Used in Pharmaceutical Industry:
[4-(chlorosulfonyl)phenoxy]acetic acid is used as an active pharmaceutical ingredient (API) for the development of anti-diabetic drugs. It functions as an orally bioavailable triaryl-sulfonamide protein tyrosine phosphatase 1B (PTP1B) inhibitor, playing a crucial role in managing blood glucose levels and improving insulin sensitivity in patients with diabetes. The inhibition of PTP1B by [4-(chlorosulfonyl)phenoxy]acetic acid helps regulate the proper functioning of insulin receptors, thereby contributing to the overall treatment and management of diabetes.

Upstream product

• 122-59-8 2-phenoxyacetic acid 

Downstream Products

• 1620001-63-9 (4-{[2-(4-bromophenyl)hydrazinyl]sulfonyl}phenoxy)acetic acid 
• 863977-54-2 [4-(4-[1,2,3]thiadiazol-4-yl-benzylsulfamoyl)-phenoxy]-acetic acid tert-butyl ester 

Relevant academic research and scientific papers

N - aryl sulfonamide compound, its pharmaceutical composition and its use (by machine translation)

The invention discloses a category represented by the following general formula I N - aryl sulfonamide compound, to the compound as the active ingredient of the pharmaceutical composition, and their preparation for treating Lp - PLA2 In the diseases related to the activity of the use. (by machine translation)

GHRH analogs

There is provided a novel series of synthetic GHRH analog peptides which are extremely potent in stimulating the release of pituitary GH in animals, including humans, which are resistant to enzymatic degradation in the body in view of the provision of the omega-guanidino lower alkyl group at the terminal 28-position of the peptide.

Synthetic GHRH analogs

Human pancreatic GRF (hpGRF), rat hypothalamic GRF (rGRF) and porcine hypothalamic GRF (pGRF) have been earlier characterized and synthesized. The invention provides synthetic peptides which are extremely potent in stimulating the release of pituitary GH in animals, including humans, which have resistance to enzymatic degradation in the body, and which have the sequence: STR1 wherein Q1 is an omega or alpha-omega substituted alkyl, Q2 is a lower omega-quanidino-alkyl group. R2 is Ala, D-Ala, or D-N-Methyl-Ala R3 is Asp, D-Asp, Glu, or D-Glu R8 is Asn, D-Asn, Ser, or D-Ser R10 is Tyr or D-Tyr R12 is Lys, D-Lys Arg or Orn R13 is Val or Ile R14 is Leu or D-Leu R15 is Gly, N-Methyl-Gly, or D-Ala R17 is Leu or D-Leu R18 is Tyr or Ser R23 is Leu or D-Leu R24 is Gln or His R25 is Asp, D-Asp, Glu, or D-Glu R27 is Met, D-Met, Ala, Nle, Ile, Val, Nva, Leu R28 is Asn or Ser The peptides as well as nontoxic salts thereof may be administered to animals, including humans and cold-blooded animals, to stimulate the release of GH and may be used diagnostically.